TUDCA,Also called tauroursodeoxycholic acid is 3α, 7β dihydroxycholanoyl-N-taurine, which is formed by the shrinkage between the carboxyl group of ursodeoxycholic acid (UDCA) and the amino group of taurine. Conjugated bile acids.
In 1902, TUDCA was discovered from bear bile, which is the main bile acid in bear bile, and has the functions of antispasmodic, anticonvulsant, anti-inflammatory and cholelitholytic. Tauroursodeoxycholic acid (tauroursodeoxycholic acid, 1) is the active ingredient of bear bile, the chemical name is 2-[[(3α, 5β, 7β)-3,7-dihydroxy-24-oxocholestane- 24-yl]amino]ethanesulfonic acid dihydrate.] Humans have been found to contain trace amounts of TUDCA. However, bear bile contains a large amount of Lyphar TUDCA. Lyphar TUDCA can reduce apoptosis and contribute to cardiac function, Huntington's disease, Parkinson's disease and stroke.
Recently, TUDCA has been found to have a protective effect on the eyes, especially in retinal degenerative diseases.Tauroursodeoxycholic acid (TUDCA) is a liver adjuvant containing 17 alkylated steroids. TUDCA is an amphiphilic bile acid. It is a taurine bound form of ursodeoxycholic acid (UDCA). Humans contain trace amounts of TUDCA. However, bear bile contains a large amount of TUDCA. TUDCA can reduce cell apoptosis, help improve heart function, protect eyes and prevent retinal degeneration.
Tauroursodeoxycholic acid (TUDCA) is a compound originally approved for the treatment of liver diseases - but recent studies have shown that it may have a wider application.
Lyphar TUDCA were first start research and put in production in 2011.
Lyphar TUDCA is closely related to ursodeoxycholic acid (UDCA), but there are some structural differences. TUDCA is one of the compounds found in bile acids. Bile acids are produced by the liver and stored in the gallbladder to aid digestion.
Recently, TUDCA is being used and tested in a wide range of therapeutic fields to explore its effectiveness. Among them, TUDCA has been studied to alleviate the symptoms of inflammatory diseases.
Interestingly, Lyphar TUDCA has been used in traditional Chinese medicine for centuries to treat a series of diseases. In traditional Chinese medicine, it was originally extracted from bear bile. Bear bile juice consists of more than 50% TUDCA. Some scientists believe that this is why bears can hibernate for a long time.
Lyphar TUDCA is now produced as a biopharmaceutical. Tudcbil (TUDCA) has 20 capsules, each containing 250 mg.
Lyphar TUDCA has been used in the treatment of liver diseases. Many available information about the role of TUDCA comes from the study of hepatocytes. The exact working principle of TUDCA has not been verified, but it is believed that it can prevent programmed cell death (also known as apoptosis).
ALS (MND) involves the gradual degeneration of nerve cells. In the same way that TUDCA prevents liver cell death, it is thought that it may slow down the process of cell death in patients with ALS, although Lyphar TUDCA's clinical trial on ALS is still in progress.
Other studies have shown that TUDCA can be used to treat the following diseases, although the research is still in progress and the treatment of many diseases has not been officially approved.
In 1902, TUDCA was discovered from bear bile, which is the main bile acid in bear bile, and has the functions of antispasmodic, anticonvulsant, anti-inflammatory and cholelitholytic. Tauroursodeoxycholic acid (tauroursodeoxycholic acid, 1) is the active ingredient of bear bile, the chemical name is 2-[[(3α, 5β, 7β)-3,7-dihydroxy-24-oxocholestane- 24-yl]amino]ethanesulfonic acid dihydrate.] Humans have been found to contain trace amounts of TUDCA. However, bear bile contains a large amount of Lyphar TUDCA. Lyphar TUDCA can reduce apoptosis and contribute to cardiac function, Huntington's disease, Parkinson's disease and stroke.
Recently, TUDCA has been found to have a protective effect on the eyes, especially in retinal degenerative diseases.Tauroursodeoxycholic acid (TUDCA) is a liver adjuvant containing 17 alkylated steroids. TUDCA is an amphiphilic bile acid. It is a taurine bound form of ursodeoxycholic acid (UDCA). Humans contain trace amounts of TUDCA. However, bear bile contains a large amount of TUDCA. TUDCA can reduce cell apoptosis, help improve heart function, protect eyes and prevent retinal degeneration.
Tauroursodeoxycholic acid (TUDCA) is a compound originally approved for the treatment of liver diseases - but recent studies have shown that it may have a wider application.
Lyphar TUDCA were first start research and put in production in 2011.
Lyphar TUDCA is closely related to ursodeoxycholic acid (UDCA), but there are some structural differences. TUDCA is one of the compounds found in bile acids. Bile acids are produced by the liver and stored in the gallbladder to aid digestion.
Recently, TUDCA is being used and tested in a wide range of therapeutic fields to explore its effectiveness. Among them, TUDCA has been studied to alleviate the symptoms of inflammatory diseases.
Interestingly, Lyphar TUDCA has been used in traditional Chinese medicine for centuries to treat a series of diseases. In traditional Chinese medicine, it was originally extracted from bear bile. Bear bile juice consists of more than 50% TUDCA. Some scientists believe that this is why bears can hibernate for a long time.
Lyphar TUDCA is now produced as a biopharmaceutical. Tudcbil (TUDCA) has 20 capsules, each containing 250 mg.
Lyphar TUDCA has been used in the treatment of liver diseases. Many available information about the role of TUDCA comes from the study of hepatocytes. The exact working principle of TUDCA has not been verified, but it is believed that it can prevent programmed cell death (also known as apoptosis).
ALS (MND) involves the gradual degeneration of nerve cells. In the same way that TUDCA prevents liver cell death, it is thought that it may slow down the process of cell death in patients with ALS, although Lyphar TUDCA's clinical trial on ALS is still in progress.
Other studies have shown that TUDCA can be used to treat the following diseases, although the research is still in progress and the treatment of many diseases has not been officially approved.